

NOURISH WITH CLINOLIPID

20% (LIPID INJECTABLE EMULSION) FOR INTRAVENOUS USE



THE OLIVE OIL-BASED ILE RICH IN OMEGA-9¹



LESS SOYBEAN OIL¹⁻⁴



MORE OLIVE OIL¹⁻⁴



110+ PUBLICATIONS⁵

Clinolipid has the lowest soybean oil and highest olive oil content of any adult indicated intravenous lipid emulsion (ILE).¹⁻⁴

Indication: CLINOLIPID injection is indicated in adults for providing a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.

Limitations of Use: CLINOLIPID injection is not indicated for use in pediatric patients because there is insufficient data to demonstrate that CLINOLIPID injection provides sufficient amounts of essential fatty acids in this population. The omega-3: omega-6 fatty acid ratio in CLINOLIPID injection has not been shown to improve clinical outcomes compared to other intravenous lipid emulsions.

CLINOLIPID 20% (Lipid Injectable Emulsion) for intravenous use Indication

CLINOLIPID injection is indicated in adults for providing a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.

Limitations of Use

CLINOLIPID injection is not indicated for use in pediatric patients because there is insufficient data to demonstrate that CLINOLIPID injection provides sufficient amounts of essential fatty acids in this population.

The omega-3: omega-6 fatty acid ratio in CLINOLIPID injection has not been shown to improve clinical outcomes compared to other intravenous lipid emulsions.

WARNING: DEATH IN PRETERM INFANTS

- Deaths in preterm infants after infusion of intravenous lipid emulsions have been reported in literature.
- Autopsy findings included intravascular fat accumulation in the lungs.
- Preterm and low birth weight infants have poor clearance of intravenous lipid emulsion and increased free fatty acid plasma levels following lipid emulsion infusion.

The use of CLINOLIPID injection is contraindicated in patients with the following:

- Known hypersensitivity to egg and soybean proteins, the lipid emulsion and/or excipients.
- Severe hyperlipidemia or severe disorders of lipid metabolism.
- Stop infusion immediately and treat patient accordingly if signs or symptoms of a hypersensitivity or allergic reaction develop.
- Monitor for signs and symptoms of fat overload, essential fatty acid deficiency (EFAD) and infections including laboratory test results

(including leukocytosis and hyperglycemia) and frequent checks of the parenteral access device.

- Carefully monitor severely undernourished patients and slowly increase their nutrient intakes, while avoiding overfeeding, to prevent refeeding complications.
- Frequent clinical and laboratory determinations are necessary throughout treatment. Monitor fluid status closely in patients with pulmonary edema or heart failure.
- Content of vitamin K may counteract anticoagulant activity.
- CLINOLIPID injection contains no more than 25 mcg/L of aluminum. There is an increased aluminum toxicity risk in patients with impaired kidney function, including preterm infants.
- Parenteral Nutrition Associated Liver Disease (PNALD) has been reported in patients who receive parenteral nutrition for extended periods of time, especially preterm infants. Monitor liver function tests. If patients develop liver test abnormalities consider discontinuation or dose reduction.
- Reduce dose of CLINOLIPID injection and monitor serum triglyceride levels in patients with serum triglyceride concentrations above 400 mg/dL to avoid clinical consequences associated with hypertriglyceridemia.
- The most common (5%) adverse drug reactions reported during CLINOLIPID injection clinical trials were nausea and vomiting, hyperlipidemia, hyperglycemia, hypoproteinemia and abnormal liver function tests.
- When admixing CLINOLIPID, protect the admixed parenteral nutrition solution from light. Use only a 1.2 micron filter to administer CLINOLIPID and admixtures containing CLINOLIPID.

Please [click here](#) for Full Prescribing Information

PRODUCT CODE	DESCRIPTION	SIZE	NDC	BAGS PER CASE	SELLING UOM	CARDINAL	MCKESSON	ABC
EADB9520	CLINOLIPID 20%	100 mL	0338-9540-05	15	Case	5579990	1565902	10229767
EADB9521	CLINOLIPID 20%	250 mL	0338-9540-06	10	Case	5580006	1565944	10229804
EADB9523	CLINOLIPID 20%	500 mL	0338-9540-07	12	Case	5580014	1565969	10229803
EADB9524	CLINOLIPID 20%	1000 mL	0338-9540-08	6	Case	5580022	1565985	10229805

FOR MORE INFORMATION ABOUT CLINOLIPID

For product information: Contact your Baxter representative

For clinical questions: Medinfo@Baxter.com

TO ORDER: 888-229-0001#1 or cfs_customer_service@baxter.com

References

1. Clinolipid (Lipid Injectable Emulsion, USP) 20% for intravenous use PI, 4/2021.
2. INTRALIPID 20% (a 20% Intravenous Fat Emulsion) and INTRALIPID 20% and 30% Pharmacy Bulk Packages (a 20% and 30% Intravenous Fat Emulsion) PI, 2022.
3. NUTRILIPID® (lipid injectable emulsion), for intravenous use PI 9/2020.
4. Smoflipid (lipid injectable emulsion), for intravenous use PI, 2022.
5. Cai W, et al. Biological and Clinical Aspects of an Olive Oil-Based Lipid Emulsion—A Review. *Nutrients*. 2018;10:776. doi:10.3390/nu10060776.

Baxter.com

Baxter and Clinolipid are trademarks of Baxter International Inc. or its subsidiaries.
US-CN6-230006 V1.0 04/2023

To discover Clinolipid,
scan the QR code below

